M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies

Not Applicable

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Thymoglobulin
Radiation: Total Lymphoid Irradiation
Procedure: Peripheral Blood Stem Cell Infusion
Drug: Rituximab

First Posted Date: 2007-05-21

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00476229

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelofibrosis

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Thymoglobulin (ATG)

First Posted Date: 2007-05-17

Last Posted Date: 2019-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 63

Registration Number: NCT00475020

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer

Completed

Conditions: Psychosocial
Cervical Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-05-16

Last Posted Date: 2020-06-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1938

Registration Number: NCT00473798

Locations: 🇺🇸
Hermann Professional Building Clinic, Houston, Texas, United States
🇺🇸
LBJ Hospital, Houston, Texas, United States
🇺🇸
Texas Medical Center Clinic, Houston, Texas, United States

and more 2 locations

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

Phase 1

Terminated

Conditions: Leukemia
Lymphoma
Myeloma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Radiation: Radiation Treatment
Procedure: Stem Cell Transplantation (SCT)
Drug: Sirolimus
Procedure: Anti-third Party Cytolytic T-lymphocytes (CTL)

First Posted Date: 2007-05-15

Last Posted Date: 2011-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00473551

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Phase 1

Completed

Conditions: Richter's Transformation
Leukemia

Interventions: Drug: Oxaliplatin
Drug: Fludarabine
Drug: Cytarabine
Drug: Rituximab
Drug: Pegfilgrastim

First Posted Date: 2007-05-14

Last Posted Date: 2013-11-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 92

Registration Number: NCT00472849

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Delayed-Immediate Breast Reconstruction

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Procedure: Delayed-Immediate Breast Reconstruction

First Posted Date: 2007-05-14

Last Posted Date: 2016-07-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT00473122

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Drug: Rituximab

First Posted Date: 2007-05-11

Last Posted Date: 2016-03-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 93

Registration Number: NCT00472056

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Phase 3

Completed

Conditions: Myelodysplastic Syndrome
Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Busulfan
Drug: Fludarabine

First Posted Date: 2007-05-04

Last Posted Date: 2021-01-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 233

Registration Number: NCT00469144

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Phase 1

Completed

Conditions: Myeloma

Interventions: Drug: Trisenox (Arsenic Trioxide)
Drug: Melphalan
Drug: Velcade (Bortezomib)
Drug: Vitamin C (Ascorbic Acid)

First Posted Date: 2007-05-04

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00469209

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Clofarabine
Drug: Busulfan
Drug: Fludarabine
Other: Stem Cell Infusion
Drug: Thymoglobulin (ATG)
Drug: Filgrastim

First Posted Date: 2007-05-04

Last Posted Date: 2021-01-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 72

Registration Number: NCT00469014

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy